Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Common Equity (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Common Equity data on record, last reported at $9.5 million in Q3 2025.

  • For Q3 2025, Common Equity rose 16.35% year-over-year to $9.5 million; the TTM value through Sep 2025 reached $9.5 million, up 16.35%, while the annual FY2024 figure was $8.8 million, 21.6% down from the prior year.
  • Common Equity reached $9.5 million in Q3 2025 per CYCN's latest filing, up from $8.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $65.2 million in Q2 2021 and bottomed at $3.9 million in Q1 2023.
  • Average Common Equity over 5 years is $21.2 million, with a median of $10.5 million recorded in 2022.
  • Peak YoY movement for Common Equity: crashed 89.4% in 2023, then soared 152.82% in 2024.
  • A 5-year view of Common Equity shows it stood at $48.2 million in 2021, then tumbled by 78.34% to $10.5 million in 2022, then rose by 8.0% to $11.3 million in 2023, then dropped by 21.6% to $8.8 million in 2024, then grew by 7.77% to $9.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $9.5 million in Q3 2025, $8.6 million in Q2 2025, and $8.8 million in Q1 2025.